Placenta-Derived NK Cells Overcome HLA-E Escape in Senescent Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing NK cell therapies, including CYNK-001, have not been investigated for their potential benefits in addressing aging-related diseases, and senescent cells escape immune surveillance by overexpressing MHC-I inhibitory ligands like HLA-E, evading elimination.
Innovation Solution
Utilizing placenta-derived NK cells with altered expression of NKG2A to overcome HLA-E mediated escape and effectively target and kill senescent cells, thereby reducing their detrimental effects on the organism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NK cells use conventional HLA-E recognition mechanisms, then they can recognize stressed cells, but senescent cells escape elimination by overexpressing HLA-E
Solution Approach 1:
The patent modifies the NK cell receptor profile by reducing or eliminating NKG2A expression while maintaining or enhancing other activating receptors. This parameter change in receptor composition allows NK cells to recognize and kill HLA-E expressing senescent cells that would otherwise escape conventional NK cell recognition.
Solution Approach 2:
The invention creates NK cell populations with non-uniform receptor expression profiles, where specific subsets of NK cells have reduced NKG2A expression compared to conventional NK cells. This local variation in receptor quality enables selective recognition of HLA-E positive targets while maintaining overall NK cell functionality.
2Adaptability or versatility
If NK cells are generated from conventional sources, then they can provide immune surveillance, but they cannot effectively target HLA-E overexpressing senescent cells
Solution Approach 1:
The patent systematically alters the receptor expression parameters of NK cells by selecting for populations with reduced NKG2A expression. This parameter modification enables the NK cells to adapt their recognition profile to effectively target HLA-E overexpressing senescent cells while maintaining versatility against other target types.
Solution Approach 2:
The invention segments the NK cell population into subsets with different receptor profiles, creating a diversified force where some cells maintain conventional HLA-E dependent recognition while others with reduced NKG2A can recognize HLA-E positive targets through alternative mechanisms.
3Quantity of substance
If senescent cells overexpress HLA-E, then they evade NK cell killing, but this creates a barrier to eliminating senescent cells in aging
Solution Approach 1:
The patent changes the immunological parameters of the attacking cells (NK cells) by modifying their HLA-E recognition profile. This enables the immune system to overcome the escape mechanism used by senescent cells and effectively eliminate them, reducing their accumulation in aging tissues.
Solution Approach 2:
The invention converts the harmful HLA-E overexpression strategy of senescent cells into a beneficial targeting mechanism. By selecting NK cells with reduced NKG2A, the system exploits the very HLA-E expression that enables escape to create a new recognition pathway that enhances senescent cell elimination.
Data Source
AI summary
Provided herein are methods of killing senescent cells, e.g., killing senescent cells in a human subject. Also provided herein are methods of treating a disease or disorder associated with cellular senescence in a subject in need thereof comprising administering to the subject an effective amount of placenta-derived NK cells to the subject. The present invention also provides compositions comprising NK, e.g., CYNK cells, for killing senescent cells and for the treatment of a disease or disorder associated with cellular senescence.